Aviva Holdings’s Solid Biosciences SLDB Stock Holding History

Aviva Holdings’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-766	Closed	-$34K	–	5
2020 Q2	$34K	Hold	766	–	–	0.01%	5
2020 Q1	$27K	Hold	766	–	–	0.01%	5
2019 Q4	$51K	Hold	766	–	–	0.01%	5
2019 Q3	$119K	Hold	766	–	–	0.03%	6
2019 Q2	$66K	Hold	766	–	–	0.01%	5
2019 Q1	$106K	Hold	766	–	–	0.02%	6
2018 Q4	$308K	Hold	766	–	–	0.1%	6
2018 Q3	$542K	Hold	766	–	–	0.14%	7
2018 Q2	$409K	Buy	+766	New	+$236K	0.07%	6

Other funds holding SLDB

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Aviva Holdings's SLDB Position: Q3 2020 in Review

Aviva Holdings sold out of Solid Biosciences (SLDB) in Q3 2020, closing a stake of 766 shares — an estimated $34K sold.

Aviva Holdings first reported a position in SLDB in Q2 2018 and held it in 9 quarters. The position peaked at $542K in Q3 2018. 62 funds tracked by Wall St. Rank hold SLDB as of Q3 2020.

Aviva Holdings reported no remaining Solid Biosciences position as of Q3 2020 after selling out during the quarter.
Aviva Holdings sold 766 Solid Biosciences shares in Q3 2020, an estimated $34K.
Aviva Holdings first reported a position in Solid Biosciences in Q2 2018 and held it in 9 quarters.
Aviva Holdings's Solid Biosciences position peaked at $542K in Q3 2018.
62 funds tracked by Wall St. Rank held Solid Biosciences as of Q3 2020.

Based on Aviva Holdings's 13F filing for Q3 2020, filed 16 Nov 2020.